These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22267984)

  • 21. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico prediction of central nervous system activity of compounds. Identification of potential pharmacophores by the TOPS-MODE approach.
    Cabrera Pérez MA; Sanz MB
    Bioorg Med Chem; 2004 Nov; 12(22):5833-43. PubMed ID: 15498659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BBB penetration-targeting physicochemical lead selection: Ecdysteroids as chemo-sensitizers against CNS tumors.
    Müller J; Martins A; Csábi J; Fenyvesi F; Könczöl Á; Hunyadi A; Balogh GT
    Eur J Pharm Sci; 2017 Jan; 96():571-577. PubMed ID: 27810561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physicochemical property profile for brain permeability: comparative study by different approaches.
    Raevsky OA; Grigorev VY; Polianczyk DE; Sandakov GI; Solodova SL; Yarkov AV; Bachurin SO; Dearden JC
    J Drug Target; 2016 Aug; 24(7):655-62. PubMed ID: 26755431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood-brain barrier drug discovery for central nervous system infections.
    Jong A; Huang SH
    Curr Drug Targets Infect Disord; 2005 Mar; 5(1):65-72. PubMed ID: 15777199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A physiologically based modeling strategy during preclinical CNS drug development.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Mol Pharm; 2014 Mar; 11(3):836-48. PubMed ID: 24446829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
    Bagchi S; Chhibber T; Lahooti B; Verma A; Borse V; Jayant RD
    Drug Des Devel Ther; 2019; 13():3591-3605. PubMed ID: 31695329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.
    Wager TT; Chandrasekaran RY; Hou X; Troutman MD; Verhoest PR; Villalobos A; Will Y
    ACS Chem Neurosci; 2010 Jun; 1(6):420-34. PubMed ID: 22778836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases.
    Ghose AK; Viswanadhan VN; Wendoloski JJ
    J Comb Chem; 1999 Jan; 1(1):55-68. PubMed ID: 10746014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occurrence of Morpholine in Central Nervous System Drug Discovery.
    Lenci E; Calugi L; Trabocchi A
    ACS Chem Neurosci; 2021 Feb; 12(3):378-390. PubMed ID: 33459557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB.
    Kimura S; Harashima H
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33334049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
    Freeman BB; Yang L; Rankovic Z
    Eur J Med Chem; 2019 Nov; 182():111643. PubMed ID: 31514017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibiotic diffusion to central nervous system].
    Cabrera-Maqueda JM; Fuentes Rumí L; Valero López G; Baidez Guerrero AE; García Molina E; Díaz Pérez J; García-Vázquez E
    Rev Esp Quimioter; 2018 Feb; 31(1):1-12. PubMed ID: 29390599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies.
    Khambhla E; Shah V; Baviskar K
    Curr Pharm Des; 2016; 22(19):2913-22. PubMed ID: 27033697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
    Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
    Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's disease drug development and the problem of the blood-brain barrier.
    Pardridge WM
    Alzheimers Dement; 2009 Sep; 5(5):427-32. PubMed ID: 19751922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Miniaturization and Automation of a Human In Vitro Blood-Brain Barrier Model for the High-Throughput Screening of Compounds in the Early Stage of Drug Discovery.
    Moya ELJ; Vandenhaute E; Rizzi E; Boucau MC; Hachani J; Maubon N; Gosselet F; Dehouck MP
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34208550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
    Kang YJ; Cutler EG; Cho H
    Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Recurrent Neural Network model to predict blood-brain barrier permeability.
    Alsenan S; Al-Turaiki I; Hafez A
    Comput Biol Chem; 2020 Dec; 89():107377. PubMed ID: 33010784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.